 |
|
Counting tumor cells in blood predicts treatment benefit in prostate cancer
July 07, 2008ESMO Conference Lugano
Counting the number of tumor cells circulating in the bloodstream of patients with castration-resistant prostate cancer can accurately predict how well they are responding to treatment, new results show.
At the ESMO Conference Lugano (ECLU) organized by the European Society for Medical Oncology, researchers showed that changes in the number of circulating tumor cells predicted the outcome after chemotherapy in this hard to treat cancer.
"The results add to a growing body of evidence showing that counting these cells is a valuable method for predicting survival and for monitoring treatment benefit in these patients", said Dr. David Olmos from The Royal Marsden NHS Foundation Trust in the UK.
"Our study shows that circulating tumor cell counts could provide information about how patients are responding to therapy earlier than other markers such as prostate-specific antigen (PSA) or time-to-disease progression," he said. "We have observed that patients with declining numbers of circulating tumor cells can see a change in their initial prognosis, reflecting a potential benefit from therapy."
Among the 119 patients in the study, researchers found that those with the lowest circulating cell counts had on average the longest survival.
"Cancer cells can be detected in the circulating blood by a range of methods", Dr. Olmos said. "The technique we used in our study is classified as a cytometric approach. We use an antibody that is widely expressed by epithelial cancer cells, and then use a range of cell-staining techniques to ensure it is a cancer cell."
"Because these circulating cells have broken away from either primary tumors or metastatic sites in other parts of the body, they could potentially be used to help study the specific characteristics of the cancer and perhaps personalize therapy", Dr. Olmos said.
European Society for Medical Oncology
"The results add to a growing body of evidence showing that counting these cells is a valuable method for predicting survival and for monitoring treatment benefit in these patients", said Dr. David Olmos from The Royal Marsden NHS Foundation Trust in the UK.
"Our study shows that circulating tumor cell counts could provide information about how patients are responding to therapy earlier than other markers such as prostate-specific antigen (PSA) or time-to-disease progression," he said. "We have observed that patients with declining numbers of circulating tumor cells can see a change in their initial prognosis, reflecting a potential benefit from therapy."
Among the 119 patients in the study, researchers found that those with the lowest circulating cell counts had on average the longest survival.
"Cancer cells can be detected in the circulating blood by a range of methods", Dr. Olmos said. "The technique we used in our study is classified as a cytometric approach. We use an antibody that is widely expressed by epithelial cancer cells, and then use a range of cell-staining techniques to ensure it is a cancer cell."
"Because these circulating cells have broken away from either primary tumors or metastatic sites in other parts of the body, they could potentially be used to help study the specific characteristics of the cancer and perhaps personalize therapy", Dr. Olmos said.
European Society for Medical Oncology
Tumor Cells Current Events and Tumor Cells News RSSTeam finds breast cancer gene linked to disease spread
A team of researchers at Princeton University and The Cancer Institute of New Jersey has identified a long-sought gene that is fatefully switched on in 30 to 40 percent of all breast cancer patients, spreading the disease, resisting traditional chemotherapies and eventually leading to death.
Salk researchers develop novel glioblastoma mouse model
Researchers at the Salk Institute for Biological Studies have developed a versatile mouse model of glioblastoma-the most common and deadly brain cancer in humans-that closely resembles the development and progression of human brain tumors that arise naturally.
UC Davis researchers find molecule that targets brain tumors
UC Davis Cancer Center researchers report today the discovery of a molecule that targets glioblastoma, a highly deadly form of cancer. The finding, which is published in the January 2009 issue of the European Journal of Nuclear Medicine and Molecular Imaging, provides hope for effectively treating an incurable cancer.
Researchers identify new anti-tumor gene
Researchers from Virginia Commonwealth University have identified a new anti-tumor gene called SARI that can interact with and suppress a key protein that is overexpressed in 90 percent of human cancers. The discovery could one day lead to an effective gene therapy for cancer.
Researcher invents lethal 'lint brush' to capture and kill cancer cells in the bloodstream
In a new tactic in the fight against cancer, Cornell researcher Michael King has developed what he calls a lethal "lint brush" for the blood -- a tiny, implantable device that captures and kills cancer cells in the bloodstream before they spread through the body.
Potential breakthrough for T-Cell lymphoma patients with drug that mimics folic acid
Preliminary results of a pivotal Phase 2 clinical trial of pralatrexate (PDX), a drug that partially works by mimicking folic acid, showed a complete or partial response in 27 percent of patients with recurrent or resistant peripheral T-cell lymphoma (PTCL).
Novel treatments show improvements in survival and response rates for leukemia and lymphoma
The use of dexamethasone early in the treatment of children with acute lymphoblastic leukemia, the most common type of childhood cancer, may help reduce the risk of relapse.
Researchers solve piece of large-scale gene silencing mystery
A team led by Craig Pikaard, Ph.D., Washington University in St. Louis professor of biology in Arts & Sciences, has made a breakthrough in understanding the phenomenon of nucleolar dominance, the silencing of an entire parental set of ribosomal RNA genes in a hybrid plant or animal.
2 new compounds show promise for eliminating breast cancer tumors
Two new compounds created by a University of Central Florida professor show early promise for destroying breast cancer tumors.
UNC researchers find clue to stopping breast-cancer metastasis
If scientists knew exactly what a breast cancer cell needs to spread, then they could stop the most deadly part of the disease: metastasis. New research from the University of North Carolina at Chapel Hill School of Medicine takes a step in that direction.
More Tumor Cells Current Events and Tumor Cells News Articles
 | Cancer Stem Cells: Novel Concepts and Prospects for Tumor Therapy (Ernst Schering Foundation Symposium Proceedings) Cancer stem cells werehave originally been identified in leukemia and later in several solid tumor types. They have very different properties from the bulk of the tumor, as they divide much more slowly and have very efficient drug- resistance mechanisms. Current treatments might largely spare cancer stem cells, thus leading to tumor recurrence and metastasis. The recent identification of growth... |
| Cellular Membranes and Tumor Cell Behavior: A Collection of Papers Presented at the 28th Annual Symposium on Fundamental Cancer Research, 1975 by Various | |
| Giant Cell Tumor of Bone : End Results Following Immunotherapy (Coley Toxins) Alone or Combined with surgery and/or Radiatino by Helen C. Nauts | |
| Gale Encyclopedia of Cancer: Giant cell tumors by Ph.D. Malini Vashishtha The article is excerpted from Gale Encyclopedia of Cancer The resource students and researchers will turn to for reliable, up-to-date and clearly written information, the Gale Encyclopedia of Cancer is a comprehensive survey of 120 cancers, cancer drugs, traditional and alternative treatments and diagnostic procedures. The Encyclopedia includes entries covering cancers, cancer drugs,... | |
 | Germ Cell Tumors (ACS ATLAS OF CLINICAL ONCOLOGY) by Derek Raghavan Crafted as a descriptive and visual text, Germ Cell Tumors features definitive reviews of the biology, diagnosis, and management of germ cell tumors. Incorporating extensive illustrations and tables, this book reviews the progress that has been made in the curative therapy of germ cell tumors over the past 25 years, progress that has lead to the positioning of germ cell tumor therapy as the... |
| Applied Imaging forms subsidiary to develop advanced technology for detecting circulating tumor cells in blood.: An article from: BIOTECH Patent News This digital document is an article from BIOTECH Patent News, published by Biotech Patent News on August 1, 2004. The length of the article is 668 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.Citation DetailsTitle:... | |
| Immunological xenogenization of tumor cells (Gann monograph on cancer research) | |
| Circulating tumor cells signal outcome in metastatic breast ca.(Gynecology): An article from: OB GYN News by Bruce Jancin This digital document is an article from OB GYN News, published by International Medical News Group on April 1, 2005. The length of the article is 524 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.Citation... | |
 | Culture of Human Tumor Cells (Culture of Specialized Cells) This comprehensive resource provides stepwise protocols for the in vitro cultivation of the major types of human tumors. Written in a reader-friendly style, this book is organized by specific tumor, discussing cultures for lung, gastric, colorectal, pancreas, bladder, prostate, ovary, cervix, mammary carcinoma, myoepithelium, squamous, melanoma, lymphoma, glioma, and neuroendocrine tumors.... |
 | Analyzing T Cell Responses: How to analyze cellular immune responses against tumor associated antigens This book reviews, describes, categorizes and provides a critical assessment of all assays that have been used for the monitoring of antigen-specific immune responses. In particular, it emphasizes a global approach to the analysis of T cell mediated target/host interactions at the systemic and the peripheral level when such interactions are supposed to occur. The book, therefore, targets a... |
| © 2009 BrightSurf.com |